ArticleInternational urogynecology journal2018

Commentary on: A cost-effectiveness analysis of onabotulinumtoxin A as first-line treatment for overactive bladder.

Abdelmageed AbdelrahmanPubMed ↗Publisher ↗

No numbers read from the abstract.